Save the world of sharks
Did you know that Sharks never run out of teeth. If one is lost, another spins forward from the rows and rows of backup teeth. A shark may grow and use over 20,000 teeth in its lifetime!
Did you know that Sharks never run out of teeth. If one is lost, another spins forward from the rows and rows of backup teeth. A shark may grow and use over 20,000 teeth in its lifetime!
Altair Nanotechnologies, Inc. (NASDAQ: ALTI), today announced that it has been awarded a $250,000 grant from the Indiana Advanced Energy Technologies Program (AETP) initiative
At long last it seems the search is over for the big question - how was the Great Pyramid built?
Scientists at NASA theorize that some 3 1/2 billion years ago, the world was changed forever. The appearance of tiny organisms with the ability to convert sunlight, warmth, water and minerals into protein, carbohydrates, vitamins and amino acids marked the beginning of life. Phytoplankton, the single-cell plants are the basis of all other life forms on planet earth;, they are the 'vegetation' of the ocean. Marine Phytoplankton are responsible for making up to 90% of Earth's oxygen. Marine phytoplankton are the food utilized by some of the world's largest and longest living animals and fish. Blue Whales, humpbacks, baleen whales and more all eat plankton and live between 80-150 years while maintaining great strength and endurance and are sexually active until they die.
Altair Nanotechnologies, Inc. (Nasdaq: ALTI) has been designated to receive an additional $2.5 million in Federal grant funding during 2006-2007 for the continued development of nanotechnology, nanosensors, and nanomaterials research, development and deployment.
Altairnano to Receive $750,000 for Development of Solar Hydrogen Generation Cells
Covance is one of the world's largest and most comprehensive drug development services and biotechnology research companies with operations currently in 17 countries. In particular, Covance is a leading provider of innovative antibody products and custom antibody development services to the research community. Visit www.Covance.com for more in-depth information.
New site aggregates pharmaceutical industry news headlines
A startling new book, Gnosis: The Secret of Solomon's Temple Revealed, by author Philip Gardiner, claims that Solomon's Temple not only didn't exist, but in fact had a much deeper significance.
Altair Nanotechnologies Inc. (NASDAQ: ALTI), today announced that its Chief Executive Officer and President, Alan J. Gotcher, Ph.D. will be speaking at the NSTI Nano Impact Summit being held October 19, 2005 in Washington DC.
Indigenous farmers in Peru, the birthplace of the potato, have slammed a move to overturn a UN moratorium on using genetically modified "Terminator" technology in agricultural production.
Altair Nanotechnologies Inc. (NASDAQ: ALTI) announced today that it will host a project update conference call
Altair Nanotechnologies Inc. (NASDAQ: ALTI), RBC Dain Rauscher issued a downgrade of the common stock price pertaining to a company covered by its research group
Altair Nanotechnologies Inc. (NASDAQ: ALTI), announced that its CEO and President, Alan J. Gotcher, Ph.D., is presenting today at ThinkEquity Partners 3rd Annual Growth Conference.
The Mars Foundation has completed an 8 month technical study of the first permanent settlement on the planet Mars.
Company Receives Research Grant of $476,850 to Continue Development on Nano-Structured Electrodes for Next Generation Batteries and Super Capacitors
SAVOIE TECHNOLAC, a science park in south-east France, is looking to develop international partnerships.
APPLEXION of France, the University of Western Sydney (UWS), Food Science Australia and Dairy Australia have joined forces to market a Franco-Australian eco-friendly dairy-processing breakthrough, which can separate the nutrients contained in whey and turn them into valuable food and pharmaceutical-grade supplements for use in medicines, healthcare and food products.
Imex Promotion of France has launched its Moon Clock® – a medal winner for its features and originality at the 2004 Paris Lépine Awards for Innovation. The clock turns at the speed of the lunar month, i.e. over 29 ½ days. It shows the time elapsing between two new or full moons. It is unique on the market, and shows at a glance the phases of the moon as well as the changes in its appearance on a day-to-day basis. With the Moon Clock ®, it is no longer necessary to rely on observations of the sky as users know precisely when the next full or new moon will be.
Florida Author - Michael Levy has written an astounding article on the Kabbalah - that will reveal the ancient secrets to any person who is curious about their views on the meaning of life.
Global publisher John Wiley & Sons, Inc., today announced the launch of the Analytical Sciences Backfile Collection, the latest addition to its growing collection of digitized journal libraries, and the second to be launched in this year. The Analytical Sciences Backfile Collection is available via Wiley InterScience (http://www.interscience.wiley.com/backfiles), Wiley’s dynamic online publishing platform.
There is no stopping the global life sciences industry. With worldwide sales of drugs crossing $500 billon, manufacturers are increasingly spending on research & development (R&D), and implementing successful strategies to acquire a greater share of this expanding industry. “New drug discovery”, “biopharmaceutical research”, “custom synthesis”, and “strategic outsourcing” are the latest industry buzzwords. In such a competitive scenario, the Indian pharmaceutical market has shown rapid growth over the years, and has established itself in the global arena. Indian fine chemical and drug manufacturers are establishing themselves as participants to be reckoned with.
Vladimir Georgiev takes over production of ProteinTrawler and proNet license distribution.
Significant performance and cost improvement implications for applications having severe durability or corrosion-resistance requirements
Callisto Pharmaceuticals, Inc. (AMEX: KAL), a biopharmaceutical company primarily focused on the development of drugs to treat cancer and osteolytic bone disease, announced today a second clinical trial of Atiprimod, its lead drug presently in a Phase I/IIa trial in relapsed multiple myeloma patients.